CTLA4 and urinary bladder carcinoma: Also, MRS was calculated in the single‐cell data using GSVA, and we compared the differences of MRS among patients with different immunotherapy responses in the three types of tumours (GSE123813: basal cell carcinoma, anti‐PD‐1; GSE145281: bladder cancer, anti‐PD‐L1; GSE120575: melanoma, anti‐PD‐1/CTLA4) (Figure 7f–k).